A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia
This study has been completed.
Sponsor:
Université de Montréal
Collaborator:
Centre hospitalier de l'Université de Montréal (CHUM)
Information provided by:
Université de Montréal
ClinicalTrials.gov Identifier:
NCT00845962
First received: February 17, 2009
Last updated: January 26, 2010
Last verified: July 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia.
| Condition | Intervention |
|---|---|
|
Spinal Anesthesia |
Drug: chloroprocaine Drug: bupivacaine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Spinal Anesthesia With Bupivacaine or 2-chloroprocaine for Outpatient Elective Surgery: a Prospective, Randomized, Double-blind Comparison. |
Resource links provided by NLM:
Drug Information available for:
Chloroprocaine
Chloroprocaine hydrochloride
Bupivacaine hydrochloride
Bupivacaine
U.S. FDA Resources
Further study details as provided by Université de Montréal:
Primary Outcome Measures:
- Time to obtain discharge criteria from recovery room [ Time Frame: within the first hours (1-2 h) after the surgery ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Time to obtain discharge criteria from hospital [ Time Frame: within the same day of the surgery ] [ Designated as safety issue: No ]
- The amount of additional IV analgesia (fentanyl) administered during the intraoperative period [ Time Frame: total length of surgery ] [ Designated as safety issue: No ]
- The amount of iv analgesia (fentanyl and morphine) needed in the recovery room [ Time Frame: lenght of stay in the recovery room ] [ Designated as safety issue: No ]
| Enrollment: | 106 |
| Study Start Date: | February 2009 |
| Study Completion Date: | July 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Chloroprocaine |
Drug: chloroprocaine
spinal administration of chloroprocaine 2%, 40 mg (2 mL)
Other Name: Nesacaine
|
| Active Comparator: Bupivacaine |
Drug: bupivacaine
spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
Other Name: Marcaine
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients aged 18 years and older
- urologic elective ambulatory procedure. For example:cystoscopy, circumcision,transurethral bladder tumor resection, varicocele and hydrocele surgery
- gynecologic elective ambulatory procedure. For example: hysteroscopy, vulvar ou vaginal biopsy
- general surgery elective ambulatory procedure. For example:inguinal herniorraphy, short ano-rectal procedure
Exclusion Criteria:
- INR > 1,3
- platelet < 75 000
- concomitant drugs: clopidogrel (last dose < 7 days), iv heparin, low molecular weight heparin (last dose < 24 hours)
- neurologic disease: spinal stenosis, symptomatic lumbar herniated disc, multiple sclerosis
- liquid restriction (cardiac or renal insufficiency)
- allergy or intolerance to chloroprocaine, bupivacaine or PABA
- atypical plasma cholinesterase or deficiency
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00845962
Locations
| Canada, Quebec | |
| St-Luc Hospital CHUM | |
| Montreal, Quebec, Canada, H2X 3J4 | |
Sponsors and Collaborators
Université de Montréal
Centre hospitalier de l'Université de Montréal (CHUM)
Investigators
| Study Director: | Jean-Denis Roy, MD | St-Luc hospital, CHUM, University of Montreal |
| Study Director: | Luc Massicotte, MD | St-Luc Hospital, CHUM, University of Montreal |
| Principal Investigator: | Marie-Andrée Lacasse, MD, resident | St-Luc hospital, CHUM, University of Montreal |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jean-Denis Roy / MD Anesthesiologist, Centre hospitalier de l'université de Montréal (CHUM) / University of Montreal |
| ClinicalTrials.gov Identifier: | NCT00845962 History of Changes |
| Other Study ID Numbers: | HD07.007, 118046 |
| Study First Received: | February 17, 2009 |
| Last Updated: | January 26, 2010 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Université de Montréal:
|
bupivacaine chloroprocaine spinal |
anesthesia elective surgery ambulatory surgery |
Additional relevant MeSH terms:
|
Anesthetics Bupivacaine Chloroprocaine Procaine Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics, Local Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013